Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
ADARx Pharmaceuticals, Inc. (ADRX) had Normalized Income after Taxes of $-73.09M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$3.45M |
|
$-73.09M |
|
-- |
|
$3.45M |
|
$91.81M |
|
$-88.36M |
|
$15.28M |
|
$-73.09M |
|
$-73.09M |
|
$-73.09M |
|
$-73.09M |
|
$-73.09M |
|
|
Normalized Income after Taxes |
$-73.09M |
$-88.36M |
|
$-88.93M |
|
9.70M |
|
9.70M |
|
$-7.54 |
|
$-7.54 |
|
| Balance Sheet Financials | |
$493.38M |
|
$4.73M |
|
$14.28M |
|
$507.65M |
|
$30.48M |
|
-- |
|
$321.80M |
|
$352.29M |
|
$-202.25M |
|
$155.37M |
|
$155.37M |
|
9.66M |
|
| Cash Flow Statement Financials | |
$262.29M |
|
$-209.93M |
|
$0.10M |
|
$14.03M |
|
$66.52M |
|
$52.48M |
|
$6.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|